Perspectives on PARP Inhibitor Combinations for Ovarian Cancer

Poly (ADP-ribose) polymerase (PARP) inhibitors constitute an important treatment option for ovarian cancer nowadays. The magnitude of benefit from PARP inhibitors is influenced by the homologous recombination status, with greater benefit observed in patients with BRCA mutated or BRCA wild-type homol...

Descripción completa

Detalles Bibliográficos
Autores principales: Bonadio, Renata Colombo, Estevez-Diz, Maria del Pilar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715945/
https://www.ncbi.nlm.nih.gov/pubmed/34976801
http://dx.doi.org/10.3389/fonc.2021.754524

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8715945/
https://www.ncbi.nlm.nih.gov/pubmed/34976801
http://dx.doi.org/10.3389/fonc.2021.754524

Ejemplares similares